Jonathan Zalevsky

Jonathan Zalevsky

Company: Nektar Therapeutics

Job title: Chief Research & Development Officer


Panel Session : Unlocking Synergies: Extending Dermatological Drug Development Insights to Address Broader Inflammatory Diseases 4:00 pm

Gain insights into the extension of knowledge from immuno-dermatological drug development to encompass a broader range of inflammatory diseases, including Rheumatoid Arthritis, Systemic Lupus Erythematosus, Inflammatory Bowel Disease and more: • How can advancements in our mechanistic understanding of dermatological drug development interactions targeting inflammatory pathways be leveraged to benefit patients with other inflammatory diseases?…Read more

day: Day One

Rezpegaldesleukin, a Regulatory T-Cell Selective IL-2 Conjugate: Lessons Learned From Preclinical Design to Clinical Evaluation in Inflammatory Skin Diseases Including Atopic Dermatitis 11:45 am

• Use of the appropriate design elements and experimental models for generation and preclinical evaluation • Using clinical development approaches to address target engagement and assess PK/PD principles • Using clinical studies to identify the correlation between the MOA and the indicationRead more

day: Day Two

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.